Transplant Diagnostics Market

Executive Summary

Transplant Diagnostics Market was valued at US $4.19 billion in 2021 and is projected to grow at 7.51% CAGR over the forecast period to reach US $6.47 billion by 2027. Transplant Diagnostics Market represented US $0.57 billion opportunity over 2019-2021 and estimated to create US $2.28 billion opportunity in 2027 over 2021.

Transplant Diagnostics from Consainsights analyses the Transplant Diagnostics Market in the Life Sciences industry over the forecast period to 2027.

Transplant Diagnostics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Transplant Diagnostics segmentation includes Technology, Product & Service, Application, Transplant Type, End User and Geography.

Based on the Technology, the Transplant Diagnostics analysis covers Molecular Assay Technologies, Non-Molecular Assay Technologies.

In Technology segment, Molecular Assay Technologies segment has highest cagr growth of 6.65%.

Based on the Product & Service, the Transplant Diagnostics analysis covers Reagents & Consumables, Instruments, Software & Services.

In Product & Service segment, Reagents & Consumables segment has highest cagr growth of 6.65%.

Based on the Application, the Transplant Diagnostics analysis covers Diagnostic Applications, Research Applications.

In Application segment, Diagnostic Applications segment has highest cagr growth of 6.65%.

Based on the Transplant Type, the Transplant Diagnostics analysis covers Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation.

In Transplant Type segment, Solid Organ Transplantation segment has highest cagr growth of 6.65%.

Based on the End User, the Transplant Diagnostics analysis covers Independent Reference Laboratories, Hospitals & Transplant Centers, Research Laboratories & Academic Institutes.

In End User segment, Independent Reference Laboratories segment has highest cagr growth of 6.65%.

Based on the region, the Transplant Diagnostics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Becton, Dickinson and Company, Biofortuna, Biomérieux SA, Bio-Rad Laboratories, Caredx, F. Hoffman-La Roche Limited, Gendx, Hologic, Inc., Illumina, Inc., Immucor, Inc., Luminex Corporation, Merck KGaA, Omixon, Qiagen Nv, Thermo Fisher Scientific, Emerging Players and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Technology

Introduction

In 2021, Molecular Assay Technologies segment has the highest revenue of US $3.27 billion and is expected to grow at CAGR of 6.65% by 2027 Molecular Assay Technologies segment has highest cagr growth of 6.65%.

Molecular Assay Technologies

Molecular Assay Technologies segment was valued at US $2.83 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $5.05 billion by 2027. Molecular Assay Technologies segment represented US $0.44 billion opportunity over 2019-2021 and estimated to create US $1.78 billion opportunity in 2027 over 2021.

Non-Molecular Assay Technologies

Non-Molecular Assay Technologies segment was valued at US $0.80 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $1.42 billion by 2027. Non-Molecular Assay Technologies segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.50 billion opportunity in 2027 over 2021.

Product & Service

Introduction

In 2021, Reagents & Consumables segment has the highest revenue of US $2.21 billion and is expected to grow at CAGR of 6.65% by 2027 Reagents & Consumables segment has highest cagr growth of 6.65%.

Reagents & Consumables

Reagents & Consumables segment was valued at US $1.91 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $3.41 billion by 2027. Reagents & Consumables segment represented US $0.30 billion opportunity over 2019-2021 and estimated to create US $1.20 billion opportunity in 2027 over 2021.

Instruments

Instruments segment was valued at US $1.10 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $1.97 billion by 2027. Instruments segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.69 billion opportunity in 2027 over 2021.

Software & Services

Software & Services segment was valued at US $0.61 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $1.09 billion by 2027. Software & Services segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Diagnostic Applications segment has the highest revenue of US $2.10 billion and is expected to grow at CAGR of 6.65% by 2027 Diagnostic Applications segment has highest cagr growth of 6.65%.

Diagnostic Applications

Diagnostic Applications segment was valued at US $1.82 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $3.24 billion by 2027. Diagnostic Applications segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.14 billion opportunity in 2027 over 2021.

Research Applications

Research Applications segment was valued at US $1.81 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $3.23 billion by 2027. Research Applications segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.14 billion opportunity in 2027 over 2021.

Transplant Type

Introduction

In 2021, Solid Organ Transplantation segment has the highest revenue of US $2.14 billion and is expected to grow at CAGR of 6.65% by 2027 Solid Organ Transplantation segment has highest cagr growth of 6.65%.

Solid Organ Transplantation

Solid Organ Transplantation segment was valued at US $1.85 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $3.30 billion by 2027. Solid Organ Transplantation segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.16 billion opportunity in 2027 over 2021.

Stem Cell Transplantation

Stem Cell Transplantation segment was valued at US $1.01 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $1.81 billion by 2027. Stem Cell Transplantation segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.64 billion opportunity in 2027 over 2021.

Soft Tissue Transplantation

Soft Tissue Transplantation segment was valued at US $0.62 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $1.10 billion by 2027. Soft Tissue Transplantation segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.39 billion opportunity in 2027 over 2021.

Bone Marrow Transplantation

Bone Marrow Transplantation segment was valued at US $0.15 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $0.27 billion by 2027. Bone Marrow Transplantation segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.09 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Independent Reference Laboratories segment has the highest revenue of US $1.99 billion and is expected to grow at CAGR of 6.65% by 2027 Independent Reference Laboratories segment has highest cagr growth of 6.65%.

Independent Reference Laboratories

Independent Reference Laboratories segment was valued at US $1.72 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $3.07 billion by 2027. Independent Reference Laboratories segment represented US $0.27 billion opportunity over 2019-2021 and estimated to create US $1.08 billion opportunity in 2027 over 2021.

Hospitals & Transplant Centers

Hospitals & Transplant Centers segment was valued at US $1.34 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $2.39 billion by 2027. Hospitals & Transplant Centers segment represented US $0.21 billion opportunity over 2019-2021 and estimated to create US $0.84 billion opportunity in 2027 over 2021.

Research Laboratories & Academic Institutes

Research Laboratories & Academic Institutes segment was valued at US $0.57 billion in 2019 and is projected to grow at 6.65% CAGR over the forecast period to reach US $1.01 billion by 2027. Research Laboratories & Academic Institutes segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.36 billion opportunity in 2027 over 2021.